DoxyPEP Resistance Risk: New Study Flags Drug-Resistant STIs

Doxycycline post-exposure prophylaxis, known as doxyPEP, has been one of the biggest wins in sexual health in years: a single pill taken after sex that cuts the risk of syphilis and chlamydia. Health agencies from the CDC to the WHO have embraced it. But a new study from Taiwan raises an uncomfortable question about the long game and a possible doxyPEP resistance problem. Researchers report that after doxyPEP was introduced at a university hospital, resistance-associated mutations in Mycoplasma genitalium, a lesser-known but fast-mutating sexually transmitted infection, started climbing.

The study, published in the International Journal of Infectious Diseases in September 2026, followed 325 doxyPEP users between September 2021 and September 2025. All were people with recent sexually transmitted infections or at risk of them, screened with a multiplex PCR assay at the hospital and offered doxyPEP counseling. According to the researchers' abstract, the detection rate of M. genitalium among all tests barely moved after doxyPEP implementation, at 6.2 percent versus 5.7 percent. Overall prevalence held steady as well, at 12.0 percent versus 12.6 percent.

The drug did not change how many people carried the infection. What shifted was the resistance picture. The share of samples carrying resistance-associated mutations to tetracycline, doxycycline's drug class, climbed from 10.0 percent to 24.1 percent. A mutation called parC, linked to fluoroquinolone resistance, edged up from 28.6 percent to 34.5 percent. Neither change reached statistical significance, which means the trends could reflect chance in a study this size. Meanwhile macrolide resistance mutations moved the other direction, falling from 33.3 percent to 13.8 percent. The authors concluded that the upward drift in tetracycline resistance "warrants continued surveillance."

Why doxyPEP became standard so fast

To see why these findings matter, it helps to know what doxyPEP is. The regimen is simple: a single 200-milligram dose of doxycycline taken within 24 hours, and no later than 72 hours, after condomless sexual contact. As reported by the European Centre for Disease Prevention and Control, clinical trials have shown it effectively reduces chlamydia and syphilis among men who have sex with men and transgender women with a history of STIs. That track record led the World Health Organization to issue its first recommendation for doxyPEP, prioritizing men who have sex with men and transgender women with recent or recurrent bacterial STIs.

The same agencies that endorsed it also flagged the trade-off. The ECDC has warned that widespread use could accelerate antimicrobial resistance not only in STI pathogens but in commensal organisms, the bacteria that naturally live on and in the body without causing harm. The agency stopped short of endorsing doxyPEP for whole populations, advising instead that decisions be made individually between a patient and a clinician.

The resistance paradox

The worry is not a sudden failure but a slow doxyPEP resistance creep, where each round of prophylaxis nudges the surviving bacteria toward harder-to-treat forms.

The Taiwan findings land in the middle of an ongoing debate among infectious disease specialists. On one side, doxyPEP prevents infections that can cause serious harm. Syphilis can damage the heart, brain, and eyes if left untreated. Chlamydia can lead to infertility. On the other side, every widespread antibiotic use creates selective pressure. Bacteria that survive the drug multiply, and resistance spreads. M. genitalium is especially tricky because it already carries high background resistance to first-line treatments like azithromycin, leaving few backup options.

The study does not suggest doxyPEP should be abandoned. The authors found no increase in M. genitalium prevalence or incidence, which indicates the drug is not fueling more infections. The concern is narrower but still serious: if tetracycline resistance keeps climbing in M. genitalium, a pathogen that is already difficult to treat could become more difficult. "The increasing trend of RAMs to tetracycline warrants continued surveillance," the researchers wrote, calling for ongoing molecular monitoring of the bacterium as doxyPEP use expands.

The WHO's own guidance reflects this tension. While recommending doxyPEP, the agency also recommends monitoring antimicrobial resistance as part of rollout, tracking both resistance trends and antibiotic use wherever feasible. In practice, that means sexual health clinics offering doxyPEP should be testing for and sequencing M. genitalium and other STI pathogens, not only handing out pills.

What this means for young people

For young adults, the message is not to avoid doxyPEP but to understand it. The regimen works best for people at high risk of bacterial STIs, and it was designed to complement condoms, regular screening, and vaccination rather than replace them. If you use doxyPEP, regular STI testing matters more, not less, because catching resistance early is the whole point of surveillance.

Talk to a clinician before starting doxyPEP on your own. The ECDC's position is that it should be an individual decision based on personal risk, made with a doctor who can monitor for resistance and side effects. If symptoms persist after treatment, say so, because resistant infections are still treatable once they are identified. The Taiwan study is a reminder that every tool in sexual health has a second act, and the job now is keeping doxyPEP's story a success.

For more on the shifting landscape of sexual health, see GenZNewz coverage of 20-minute STI testing in Australia and the syphilis surge in Japan.

Sources: PubMed, "Impact of doxycycline post-exposure prophylaxis on the prevalence of resistance-associated mutations of Mycoplasma genitalium"; ECDC guidance on doxycycline for STI prevention; Medscape, "WHO Recommends Doxycycline PEP to Prevent Bacterial STIs".